REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on Tuesday

REGENXBIO (NASDAQ:RGNX) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.19) per share and revenue of $23.70 million for the quarter.

REGENXBIO Stock Down 1.2 %

Shares of RGNX opened at $7.27 on Monday. The business’s 50-day moving average price is $7.70 and its 200-day moving average price is $9.59. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The stock has a market cap of $360.16 million, a PE ratio of -1.45 and a beta of 1.29.

Wall Street Analyst Weigh In

RGNX has been the topic of several analyst reports. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. Morgan Stanley restated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of REGENXBIO in a research report on Wednesday, January 15th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.45.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.